GlassScriptPhysician profile
Carla Chong
NPI 1114228517
$3,840.00
in general payments reported to CMS, 2019-2025
34 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $1,121 · 2023: $1,014 · 2024: $960 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $554.41 | 2022 | |
| Abbvie INC. | $455.93 | 2021-2024 | |
| Nevro Corp. | $423.07 | 2021-2023 | Senza |
| Medtronic, INC. | $285.09 | 2021-2025 | Minimed 780g, Venaseal, Simplera Sensor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.61 | 2023-2024 | Jardiance, Synjardy |
| Corcept Therapeutics | $227.73 | 2023-2024 | Korlym |
| Abbott Laboratories | $208.19 | 2021-2024 | Freestyle Libre 3, Eterna, Proclaim |
| Lilly USA, LLC | $182.39 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $172.05 | 2021-2024 | Tepezza, Repatha |
| Mannkind Corporation | $165.74 | 2023-2024 | V-Go, Afrezza |
| Xeris Pharmaceuticals, INC. | $161.83 | 2023-2024 | Recorlev |
| Collegium Pharmaceutical, INC. | $127.78 | 2022-2025 | Xtampza |
| Novo Nordisk INC | $74.30 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $64.87 | 2024-2025 | Ingrezza |
| Solventum Corporation | $62.97 | 2025 | Promogran Prisma, Activ.A.C. |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.22 | 2024-2025 | |
| Koya Medical, INC. | $43.24 | 2025 | Koya Medical, Dayspring |
| Recordati_rare_diseases_inc. | $38.13 | 2024 | Signifor Lar, Isturisa |
| Radius Health, INC. | $29.33 | 2024 | Tymlos |
| Antares Pharma, INC. | $23.81 | 2024 | Xyosted |
| Forte Bio-Pharma LLC | $23.50 | 2021 | |
| Kyowa Kirin, INC. | $19.61 | 2023 | Crysvita |
| Saluda Medical Americas, INC. | $19.09 | 2025 | Evoke |
| Bayer Healthcare Pharmaceuticals INC. | $18.61 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.22 | 2022 | |
| Stimwave Technologies Incorporated | $18.03 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.00 | 2022 | |
| Averitas Pharma INC. | $17.62 | 2023 | Qutenza |
| Mallinckrodt Hospital Products INC. | $16.62 | 2025 | Acthar |
| Tactile Systems Technology INC | $14.99 | 2024 | Flexitouch Plus, Entre Plus |
| Horizon Therapeutics Plc | $14.79 | 2023 | Tepezza |
| Arbor Pharmaceuticals, INC. | $14.28 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.87 | 2023 | Strensiq |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.